Summary:
FLOW is a clinical study, which will include over 3,000 people with type 2 diabetes
from 28 countries worldwide and will run for approximately 5 years.
The FLOW study is being carried out to see if semaglutide can reduce the worsening
or progression of kidney disease in people with type 2 diabetes. A previous study has
shown that using semaglutide reduced the progression of kidney disease and the risk
of cardiovascular events in some people with type 2 diabetes. Semaglutide is already
approved in some countries to treat type 2 diabetes.
Qualified Participants Must:
• Be 18 years of age or older
•
Have been diagnosed with Type 2 Diabetes
•
Impaired kidney function (GFR 50-75)
Qualified Participants May Receive:
• ability to ake a more active role in your own healthcare
• regular expert medical care at healthcare facilities
• additional talks with study staff to discuss healthy lifestyle choices
• the trial medication, care, and labs for free
Compensation for time and travel for each competed visit